Richard Hague compensation by year
Anika Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Salary | $315,000 | $326,025 | $335,806 |
| Bonus | $127,575 | $102,698 | $105,779 |
| Stock awards | $301,069 | $0 | $0 |
| Option awards | $439,830 | $599,331 | $363,305 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $84,799 | $27,096 | $22,346 |
| Total | $1,268,273 | $1,055,150 | $827,236 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Anika Therapeutics, Inc. DEF 14A filed April 25, 2019, accession 0001171843-19-002640, and prior-year filings.
How this page was built: the Anika Therapeutics, Inc. filed document, accession 0001171843-19-002640. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2019.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 5,250 | $176,453 | — |
| RSU | 3,950 | $132,760 | — |
| Option | 14,477 | — | $61.47 |
| Option | 20,192 | — | $50.13 |
| Option | 14,900 | — | $38.11 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Anika Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.
Anika Therapeutics’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Charles Sherwood | Former Chief Executive Officer | $4,997,178 |
| Joseph Darling | Chief Executive Officer and President | $2,170,187 |
| Sylvia Cheung | Chief Financial Officer and Treasurer | $1,287,202 |
| Edward Ahn | Chief Technology and Strategy Officer | $913,590 |
| Richard Hague · this page | Chief Commercial Officer | $827,236 |
| Thomas Finnerty | Chief Human Resources Officer | $758,633 |
The full Anika Therapeutics compensation record
free company briefThis page is one person within Anika Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Anika Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Anika Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.